Century Therapeutics, Inc.
NASDAQ:IPSCBiotechnology
+$0.01 today
- Market cap
- $250.60M
- Beta
- 1.57
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.25
Volume 1.14M
Average 1.12M
IPSC Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Century Therapeutics, Inc.NASDAQ: IPSC
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$21.65M, compared with $76.56M a year earlier. Trailing-twelve-month net income was -$107.79M. Over 3 fiscal years it compounded at -58.2% a year.
Context
- Net income amounted to 8.8% of revenue in FY2025, down 1912.1 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$44.41M (+363.5%) for the fiscal year ending Dec 2026, a step up from the -92.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$21.65M+12.9% QoQ
- Last fiscal yearDec 2025
- -$9.58M-92.4% YoY
- LTMMar 2026
- -$107.79M+391.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (9.58M) USD
- Year-over-year change
- +92.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.58M) | +92.4% |
| FY2024 | 2024-12-31 | (126.57M) | +7.4% |
| FY2023 | 2023-12-31 | (136.67M) | -4.4% |
| FY2022 | 2022-12-31 | (130.93M) | -36.6% |
| FY2021 | 2021-12-31 | (95.82M) | — |
Net Income vs competitors
How IPSC compares with its peers on the latest reported figures
- IPSC's LTM Mar 2026 net income of $107.79M is the 3rd largest of the 8 companies compared; the peer median is $19.52M.
- Its year-over-year change of +391.1% is the 2nd highest of 8, against a peer median of +12.6%.
- Over three fiscal years its annual growth of -58.2% compares with a peer median of -1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $28.76B | +254398.4% | +1562.8% | — |
| LTM Mar 2026 | $194.97M | +211.8% | +5.9% | 129.0% | |
| LTM Mar 2026 | $107.79M | +391.1% | -58.2% | — | |
| LTM Mar 2026 | $60.96M | -388.6% | -1.9% | 18297.5% | |
| LTM Mar 2026 | $19.52M | -51.9% | -20.5% | 59.6% | |
| LTM Mar 2026 | $19.06M | +36.2% | -28.9% | — | |
| LTM Mar 2026 | $12.72M | +12.6% | -31.8% | 899.5% | |
| LTM Mar 2026 | $9.22M | -26.0% | +130.2% | — | |
| Peer median (excluding IPSC) | $19.52M | +12.6% | -1.9% | 514.2% | |
Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (95.82M) | (130.93M) | (136.67M) | (126.57M) | (9.58M) |
| Depreciation & Amortization | 3.75M | 8.44M | 13.04M | 13.3M | 13.1M |
| Deferred Income Tax | 0 | 0 | 0 | 870K | (73K) |
| Stock-Based Compensation | 4.66M | 10.67M | 14.62M | 12.69M | 6.84M |
| Change in Working Capital | (2.8M) | 123.95M | 9.38M | (9.28M) | (114.55M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.85M) | (4.79M) | (2.36M) | (1.47M) | 1.56M |
| Other Working Capital | (949K) | 128.73M | 11.74M | (7.81M) | (116.12M) |
| Other Non-Cash Items | 1.21M | 1.93M | 11.28M | (1.15M) | 389K |
| Operating Cash Flow | (89M) | 14.05M | (88.35M) | (110.14M) | (103.88M) |
| Capital Expenditures | (44.97M) | (30.6M) | (13.74M) | (154K) | (848K) |
| Acquisitions (Net) | 0 | (238.22M) | 0 | (9.61M) | 0 |
| Purchases of Investments | (330.03M) | (254M) | (209.03M) | (119.55M) | (51.17M) |
| Sales of Investments | 76.67M | 271.48M | 283.9M | 176.79M | (51.17M) |
| Other Investing Activities | 0 | 238.22M | 0 | 0 | 210.7M |
| Investing Cash Flow | (298.34M) | (13.13M) | 61.13M | 47.48M | 107.5M |
| Debt Repayment | 0 | 0 | (10.24M) | 0 | 0 |
| Common Stock Issued | 221.62M | 27.16M | 516K | 74.56M | 173K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 36.53M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 417.77M | 27.16M | (9.73M) | 74.56M | 173K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 30.43M | 28.08M | (36.94M) | 11.91M | 3.8M |
| Free Cash Flow | (133.97M) | (16.55M) | (102.08M) | (110.29M) | (104.72M) |
Century Therapeutics, Inc.
NASDAQ:IPSC
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.